Reimbursement Review Reports

The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

For each drug, plasma product, or cell and gene therapy reviewed in the Drug Reimbursement Review process, there is an opportunity for patient groups and clinician groups to provide input and feedback. See Reimbursement Review Open Calls for Input and Feedback.

Brand Name Sort descending Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Brilinta Ticagrelor Acute Coronary Syndromes Cancelled
Brilinta Ticagrelor Acute coronary syndromes Do not list Complete
Brilinta ticagrelor Prevention of atherothrombotic events with history of myocardial infarction Reimburse with clinical criteria and/or conditions Complete
Brineura cerliponase alfa Neuronal Ceroid Lipofuscinosis Type 2 Reimburse with clinical criteria and/or conditions Complete
Brivlera Brivaracetam Epilepsy, partial-onset seizures Reimburse with clinical criteria and/or conditions Complete
Brukinsa zanubrutinib Mantle cell lymphoma (MCL) Do not reimburse Complete
Brukinsa zanubrutinib Relapsed or refractory follicular lymphoma Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission. Not filed
Brukinsa zanubrutinib Chronic lymphocytic leukemia /small lymphocytic lymphoma. Reimburse with clinical criteria and/or conditions Complete
Brukinsa zanubrutinib Waldenström’s macroglobulinemia Reimburse with clinical criteria and/or conditions Complete
BuTrans Buprenorphine transdermal patch Pain, persistent (moderate intensity) Cancelled